Buys | $0 | 0 | 0 |
Sells | $1,119,351 | 15 | 100 |
Delfini Lisa | Chief Financial Officer | 0 | $0 | 1 | $11,485 | $-11,485 |
Meeker David P | director | 0 | $0 | 1 | $13,353 | $-13,353 |
SCIASCIA THOMAS | Chief Scientific Officer | 0 | $0 | 5 | $272,220 | $-272,220 |
GOOD JENNIFER L | President & CEO | 0 | $0 | 7 | $273,416 | $-273,416 |
Simon Farrell | Chief Commercial Officer | 0 | $0 | 1 | $548,878 | $-548,878 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in …
Over the last 12 months, insiders at Trevi Therapeutics, Inc. have bought $0 and sold $1.12M worth of Trevi Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Trevi Therapeutics, Inc. have bought $22.8M and sold $388,241 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,631,578 shares for transaction amount of $5M was made by NEA 16 GP, LLC () on 2022‑04‑11.
2025-03-10 | Sale | Simon Farrell | Chief Commercial Officer | 81,313 0.1012% | $6.75 | $548,878 | +3.79% | |
2024-09-09 | Sale | GOOD JENNIFER L | President & CEO | 1,840 0.0025% | $3.04 | $5,587 | +10.26% | |
2024-09-06 | Sale | GOOD JENNIFER L | President & CEO | 4,219 0.006% | $3.03 | $12,784 | +16.10% | |
2024-09-05 | Sale | GOOD JENNIFER L | President & CEO | 40,277 0.0557% | $3.11 | $125,310 | +10.00% | |
2024-09-04 | Sale | GOOD JENNIFER L | President & CEO | 10,981 0.0155% | $3.02 | $33,205 | +14.92% | |
2024-09-03 | Sale | GOOD JENNIFER L | President & CEO | 3,863 0.0054% | $3.02 | $11,677 | +13.47% | |
2024-08-27 | Sale | Meeker David P | director | 4,555 0.0063% | $2.93 | $13,353 | +14.78% | |
2024-08-19 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 16,496 0.0227% | $2.96 | $48,883 | +11.11% | |
2024-08-16 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 18,660 0.0268% | $2.76 | $51,440 | +19.13% | |
2024-08-15 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 12,745 0.0185% | $2.79 | $35,513 | +20.00% | |
2024-08-14 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 100 0.0001% | $2.75 | $275 | +26.44% | |
2024-05-29 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 53,368 0.0761% | $2.55 | $136,110 | +22.05% | |
2024-05-22 | Sale | Delfini Lisa | Chief Financial Officer | 4,350 0.0062% | $2.64 | $11,485 | +16.23% | |
2024-05-20 | Sale | GOOD JENNIFER L | President & CEO | 25,037 0.0359% | $2.86 | $71,576 | +8.83% | |
2024-05-10 | Sale | GOOD JENNIFER L | President & CEO | 4,578 0.0069% | $2.90 | $13,276 | +11.36% | |
2023-10-11 | Sale | Delfini Lisa | Chief Financial Officer | 785 0.0012% | $2.02 | $1,586 | +32.11% | |
2023-09-11 | Sale | Delfini Lisa | Chief Financial Officer | 711 0.0011% | $2.20 | $1,564 | +15.27% | |
2023-08-11 | Sale | Delfini Lisa | Chief Financial Officer | 682 0.0011% | $2.36 | $1,610 | -1.05% | |
2023-07-11 | Sale | Delfini Lisa | Chief Financial Officer | 687 0.0007% | $2.34 | $1,608 | +0.55% | |
2023-06-12 | Sale | Delfini Lisa | Chief Financial Officer | 610 0.0006% | $2.64 | $1,610 | -11.72% |
Meeker David P | director | 352489 0.3944% | $2.22M | 1 | 1 | <0.0001% |
GOOD JENNIFER L | President & CEO | 213313 0.2387% | $1.34M | 1 | 7 | <0.0001% |
BASKETT FOREST | 10421428 11.6616% | $65.55M | 3 | 1 | +1.73% | |
Makhzoumi Mohamad | 10421428 11.6616% | $65.55M | 3 | 1 | +1.73% | |
NEA 16 GP, LLC | 10421428 11.6616% | $65.55M | 1 | 0 | <0.0001% |
$36,510,315 | 95 | 8.95% | $600.23M | |
$587,109,125 | 90 | 3.17% | $509.59M | |
$14,527,743 | 76 | 38.40% | $473.67M | |
Trevi Therapeutics, Inc. (TRVI) | $678,065,999 | 37 | -13.32% | $562.11M |
$94,912,877 | 34 | -7.15% | $605.37M |
Increased Positions | 74 | +98.67% | 28M | +47.62% |
Decreased Positions | 31 | -41.33% | 6M | -10.48% |
New Positions | 27 | New | 13M | New |
Sold Out Positions | 8 | Sold Out | 260,157 | Sold Out |
Total Postitions | 118 | +57.33% | 80M | +37.14% |
Nea Management Company, Llc | $51,394.00 | 12.78% | 11.37M | 0 | 0% | 2024-12-31 |
Frazier Life Sciences Management, L.P. | $48,205.00 | 11.98% | 10.66M | +3M | +44.49% | 2024-12-31 |
Viking Global Investors Lp | $19,888.00 | 4.94% | 4.4M | 0 | 0% | 2024-12-31 |
Rubric Capital Management Lp | $19,007.00 | 4.72% | 4.21M | -821,802 | -16.35% | 2024-12-31 |
Point72 Asset Management, L.P. | $18,759.00 | 4.66% | 4.15M | +4M | New | 2024-12-31 |
Blackrock, Inc. | $17,757.00 | 4.41% | 3.93M | +706,710 | +21.94% | 2024-12-31 |
Vanguard Group Inc | $15,862.00 | 3.94% | 3.51M | +246,832 | +7.57% | 2024-12-31 |
Vivo Capital, Llc | $15,765.00 | 3.92% | 3.49M | +2M | +116.25% | 2024-12-31 |
Woodline Partners Lp | $14,521.00 | 3.61% | 3.21M | +3M | +429.93% | 2024-12-31 |
Mpm Bioimpact Llc | $13,989.00 | 3.48% | 3.09M | +2M | +101.16% | 2024-12-31 |